Areci RJ. Progress and controversies in the treatment of pediatric acute myelogenous leukemia. Curr Opin Hematol 2002;9:353-60.
Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MC, Johnston K, Erdmann GR, Gold S, Heerema NA, Hutchinson RJ, Provisor A, Trigg ME. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003;101:3809-3817.
Cavé H, Bosch JWDW, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thelemans K, Grandchamp B, Vilmer E. Clinical significance of minimal residual disease in childhood ALL. N Engl J Med 1998;339:591-8.
Chessells JM. Relapsed lymphoblastic leukemia in children: a continuing challenge. Br J Haematol 1998;102:423-38.
Clark JJ, Smith FO, Arceci RJ. Update in childhood acute myeloid leukemia: recent developments in the molecular basis of disease and novel therapies. Curr Opin Hematol 2003;10:31-9.
de Boton S, Coiteux V, Chevret S, Rayon C, Vilmer E, et al. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J Clin Oncol 2004;15;22(8):1404-12.
Gaynon PS, Qu RP, Chappell RJ, Willoughby RLN, Tubergen DG, Steinherz PG, Trigg ME. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse—the Children's Cancer Group experience. Cancer 1998;82:1387-95.
Gaynon PS, Trigg ME, Heerema NA, Sensel MG, Sathei HN, Hammond GD, Bleyer WA. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000;14:2223-33.
Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, Cohen HJ, Salan SE, Asselin BL. Childhood T-cell acute lymphoblastic leukemia: the Dana Farber Cancer Institute. Acute lymphoblastic leukemia consortium experience. J Clin Oncol 2003;21:3616-22.
Golub TR, Areci RJ. Acute myelogenous leukemia. In: Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott-Williams and Wilkin, 2002;545-90.
Harris RE, Sather HN, Feig SA. High dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: the Children's Cancer Group experience. Med Pediatr Oncol 1998;30:233-9.
Margolin JF, Poplack DG. Acute lymphoblastic leukemia. In: Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott-Williams and Wilkin, 2002;489-544.
Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, Wolff L, Uckun FM, Gaynon PS. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998;338:1663-71.
Patte C, Auperin A, Michon J, Behrendt, H et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B cell lymphomas and L3 leukemia. Blood 2001;97:3370-9.
Pui CH. NCCN pediatric acute lymphoblastic leukemia practice guidelines. Oncology 1996;10:1787-94.
Pui CH, Gaynon PS, Boyett JM, Chesells JM, Baruchel A, Kamps W, Silverman LB, Biondi A, Harms DO, Vilmer E, Schrappe M, Camitta B. Outcome of treatment in childhood acute lymphoblastic leukemia with rearrangements of the 11q23 chromosomal region. Lancet 2002;359:1909-15.
Pui CH, Relling MV, Downing JR. Mechanisms of disease: acute lymphoblastic leukemia. N Engl J Med 2004;350:1535-48.
Ritchey AK, Pollock BH, Lauer SJ, Andejeski Y, Buchanan GR. Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol 1999;17:3745-52.
Rubnitz JE, Look AT. Molecular genetics of childhood leukemia. J Pediatr Hematol Oncol 1998;20:1-11.
Rubnitz JE, Pui CH. Recent advances in the treatment and understanding of childhood acute lymphoblastic leukemia. Cancer Treatment Rev 2003;29:31-44.
Sievers EL. Antibody-targeted chemotherapy of acute myeloid leukemia using gem-tuzumab ozogamicin (Mylotarg). Blood Cells Mol Dis 2003;31:7-10.
Silvermann LB, Sallen SE. Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment. Curr Opin Hematol 2003;10:290-6.
Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui CH, Pullen J, Reaman G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18-24.
Steinherz PG, Redner A, Steinherz L, Meyers P, Tan C, Heller G. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. Cancer 1993;72:3120-30.
Stevens RF, Hahn IM, Wheatley K, Grayon RG. Marked improvements in outcome with chemotherapy alone in paediatric acute leukemia: results of the United Kingdom Medical Research Councils 10th AML trial. Br J Haematol 1998;101:130-40.
Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2300.
Webb KH, Harison G, Stevens RF, Gibson BG, Hann IM, Wheatley K. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood 2001;98:1714-20.
Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J, Buxton AB, Dusenbery K, Gamis A, Masterson M, Vik T, Warkentin P, Whitlock JA. Mitoxanthrone cytara-bine induction, high-dose cytarabine and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia. Children's Oncology Study Group 2951. J Clin Oncol 2003;21:2940-7.
Wofford MM, Smith SD, Shuster JJ, Johnson W, Buchanan GR, Wharam MD, Richey AK, Rosen D, Haggard ME, Golembe BL, Rivera GK. Treatment of occult or late overt testicular relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1992;10:624-30.
Woods WG, Kobrinsky N, Buckley JD, Lee JW, Sanders J, Neudorf S, Gold S, Barnard DR, DeSwarte J, Dusenbery K, Kalousek D, Arthur DC, Lange BJ. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood 1996;87:4979-89.
Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, Dusenbery K, DeSwarte J, Arthur DC, Lange BJ, Kobrinsby NL. A comparison of allogeneic bone marrow transplantation and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer Group. Blood 2001;97:56-61.
Was this article helpful?
Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.